10.35
Liminatus Pharma Inc stock is traded at $10.35, with a volume of 113.20K.
It is down -7.17% in the last 24 hours and up +90.61% over the past month.
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing cancer therapies and treatments. The GCC Vaccine of the company is in Phase II of clinical trials designed for immune behavior towards colorectal, pancreatic, gastric, and esophageal cancers that express Guanylyl Cyclase C.
See More
Previous Close:
$11.15
Open:
$11.78
24h Volume:
113.20K
Relative Volume:
0.71
Market Cap:
$333.25M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-61.19%
1M Performance:
+90.61%
6M Performance:
+0.00%
1Y Performance:
+0.00%
Liminatus Pharma Inc Stock (LIMN) Company Profile
Name
Liminatus Pharma Inc
Sector
Industry
Phone
213-273-5453
Address
6 CENTERPOINTE DR., LA PALMA
Compare LIMN with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
LIMN
Liminatus Pharma Inc
|
10.35 | 333.25M | 0 | 0 | 0 | 0.00 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Liminatus Pharma Inc Stock (LIMN) Latest News
Why Is Liminatus Pharma Inc (LIMN) Up 83%? Unpacking the Surge - Wealth Daily
KH Group's investment in US biotech Liminatus Pharma halves in one day - Chosun Biz
Liminatus Pharma Stock Surges to Record High After Regaining Nasdaq Compliance - MSN
Liminatus Pharma stock gains on regaining compliance with Nasdaq - MSN
Greif Posts Upbeat Earnings, Joins Planet Labs PBC, IperionX, Owens & Minor And Other Big Stocks Moving Higher On Thursday - Benzinga
Crude Oil Moves Higher; Ciena Posts Downbeat Earnings - Benzinga
Dow Dips Over 100 Points; US Jobless Claims Increase - Benzinga
Liminatus Pharma shares soar on Nasdaq compliance news By Investing.com - Investing.com Canada
Liminatus Pharma shares soar on Nasdaq compliance news - Investing.com Australia
Pre-market Movers: LIMN, KRON, HSDT, CBUS... - RTTNews
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Liminatus Pharma Gains Compliance With Nasdaq Filing Requirements; Shares up Pre-Bell - marketscreener.com
Liminatus Pharma regains Nasdaq listing compliance - TipRanks
Liminatus Pharma Regains Nasdaq Compliance After Filing Delay - TipRanks
Liminatus Pharma, Inc.Class A Common Stock (Nasdaq:LIMN) Stock Quote - FinancialContent
Liminatus Pharma Delays Quarterly Report Filing - TipRanks
Liminatus Pharma’s Merger with Iris Acquisition Corp. - Global Legal Chronicle
Iris Acquisition, Liminatus Pharma Sign SPAC Merger Deal - marketscreener.com
LIMN Stock Price and Chart — NASDAQ:LIMN - TradingView
Iris Acquisition Corp confirms delisting and shareholder vote outcomes - Investing.com
Iris Acquisition Corp announces preliminary proxy statement - Investing.com
Iris Acquisition Corp announces business combination - Investing.com
Iris Acquisition Corp announces business combination with Liminatus Pharma - Investing.com
New company Liminatus Pharma Inc to develop three cancer treatments - Labiotech.eu
A fledgling biotech goes SPAC route to bankroll cancer vaccine, CAR-T and CD47 - Endpoints News
Liminatus Pharma and Iris Acquisition to Combine in $334M Deal - The SPAC Conference
Liminatus Pharma and Iris Acquisition Corp to Combine - citybiz
Holland & Knight Partner Seth Belzley Ranked Among Denver’s Outstanding "40 Under 40" Business Professionals - Holland & Knight
Liminatus Pharma Inc Stock (LIMN) Financials Data
There is no financial data for Liminatus Pharma Inc (LIMN). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):